María Dolores Martín-Arranz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
María Dolores Martín-Arranz has a total of 888 co-authors. Here are the top co-authors by number of shared publications:
- Javier P. Gisbert
Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM) , Madrid
20 shared publications - María Chaparro
Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM) , Madrid
14 shared publications - Manuel Barreiro-De Acosta
Department of Gastroenterology Complexo Hospitalario Universitario de Santiago and Fundación Instituto de Investigación Sanitaria de Santiago de Compostela (FIDIS) Santiago de Compostela Spain
13 shared publications - Alejandro Hernández-Camba
Hospital Nuestra Señora de La Candelaria
12 shared publications - Ana Gutiérrez
Department of Gastroenterology, CIBEREHD, Hospital General Universitario Dr. Balmis, Alicante, Spain
11 shared publications - José María Huguet
Department of Gastroenterology, Hospital General Universitario de Valencia, Valencia, Spain
11 shared publications
Latest Publications
- Open Access
- 11 October 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
Clinical Course and Predictors of Biologic Therapy, Hospitalisation and Surgery: A Five‐Year Prospective Study in Newly Diagnosed Inflammatory Bowel Disease
Aims: This study aimed to describe the characteristics of newly diagnosed inflammatory bowel disease (IBD) patients and to analyse their clinical course within the first 5 years after diagnosis, including the need for surgery, hospitalisations and treatments. Methods: This prospective and large multicentre incident cohort registry in Spain enrolled adults diagnosed with Crohn's disease (CD), ulcerative colitis (UC) or unclassified IBD (IBD‐U) in 2017 and followed them for 5 years. Results: A total of 3301 patients were enrolled: 1526 with CD, 1633 with UC and 142 with IBD‐U. Their median age at diagnosis was 43 years (interquartile range 31–56) and approximately 50% were male. Within 5 years post‐diagnosis, 30% received biologics or JAK inhibitors (JAKi), 34% were hospitalised at least once and 9% underwent surgery. The cumulative incidence of biologic/JAKi treatment, hospitalisations and surgeries was higher among CD patients. Use of biologics/JAKi correlated with a more aggressive CD phenotype, greater UC extent and younger age at diagnosis. Biologics/JAKi treatment was associated with lower hospitalisation risk in both CD (Hazard ratio [HR] = 0.4, 95% confidence interval [CI] = 0.2–0.6) and UC patients (HR = 0.5, 95% CI = 0.2–0.9). However, it was not associated with the risk of abdominal surgery in CD but was linked to an increased risk of surgery in UC (HR = 11.9, 95% CI = 4.6–30.4). Conclusions: This large multicentre cohort demonstrated a higher use of biologics/JAKi during the first 5 years after IBD diagnosis than previously reported. Treatment with biologics/JAKi was associated with reduced risk of hospitalisation. However, under current clinical practice patterns, this therapeutic approach did not translate into lower risk of abdominal surgery.
- 11 October 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
Open AccessClinical Course and Predictors of Biologic Therapy, Hospitalisation and Surgery: A Five‐Year Prospective Study in Newly Diagnosed Inflammatory Bowel Disease
Aims: This study aimed to describe the characteristics of newly diagnosed inflammatory bowel disease (IBD) patients and to analyse their clinical course within the first 5 years after diagnosis, including the need for surgery, hospitalisations and treatments. Methods: This prospective and large multicentre incident cohort registry in Spain enrolled adults diagnosed with Crohn's disease (CD), ulcerative colitis (UC) or unclassified IBD (IBD‐U) in 2017 and followed them for 5 years. Results: A total of 3301 patients were enrolled: 1526 with CD, 1633 with UC and 142 with IBD‐U. Their median age at diagnosis was 43 years (interquartile range 31–56) and approximately 50% were male. Within 5 years post‐diagnosis, 30% received biologics or JAK inhibitors (JAKi), 34% were hospitalised at least once and 9% underwent surgery. The cumulative incidence of biologic/JAKi treatment, hospitalisations and surgeries was higher among CD patients. Use of biologics/JAKi correlated with a more aggressive CD phenotype, greater UC extent and younger age at diagnosis. Biologics/JAKi treatment was associated with lower hospitalisation risk in both CD (Hazard ratio [HR] = 0.4, 95% confidence interval [CI] = 0.2–0.6) and UC patients (HR = 0.5, 95% CI = 0.2–0.9). However, it was not associated with the risk of abdominal surgery in CD but was linked to an increased risk of surgery in UC (HR = 11.9, 95% CI = 4.6–30.4). Conclusions: This large multicentre cohort demonstrated a higher use of biologics/JAKi during the first 5 years after IBD diagnosis than previously reported. Treatment with biologics/JAKi was associated with reduced risk of hospitalisation. However, under current clinical practice patterns, this therapeutic approach did not translate into lower risk of abdominal surgery.
- 10 June 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 64 (6) , 781-791
Real‐World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA Registry
Background and Aims: Risankizumab, a selective interleukin‐23 p19 inhibitor, has demonstrated efficacy in clinical trials for moderate‐to‐severe Crohn's disease, but real‐world data in highly refractory populations are limited. We evaluated the short‐term effectiveness and outcomes at last follow‐up of risankizumab and the impact of prior advanced therapy exposure. Methods: This multicentre observational study included adult patients with predominantly refractory Crohn's disease treated with risankizumab and registered in the ENEIDA registry. Steroid‐free clinical remission, defined as a Harvey–Bradshaw Index ≤ 4 without systemic corticosteroids, was assessed at weeks 8–12 and at the last available follow‐up visit. Multivariable logistic regression was used to identify factors associated with remission at last follow‐up. Results: A total of 857 patients with predominantly refractory Crohn's disease were included. Steroid‐free clinical remission was achieved in 56% of patients at weeks 8–12 and in 61% at last follow‐up (mean follow‐up: 7.4 months). Remission rates were higher in patients previously exposed to ≤ 2 biologic therapies than in those exposed to > 2 biologic therapies at both time points ( p < 0.001). Prior ustekinumab exposure was associated with lower remission rates in unadjusted analyses but was not independently associated with remission at last follow‐up. Treatment‐related adverse events occurred in 8% of patients, with no serious adverse events. Conclusions: In this large real‐world cohort of patients with refractory Crohn's disease, risankizumab achieved clinically meaningful steroid‐free clinical remission, both at early assessment and at last follow‐up, with effectiveness primarily influenced by cumulative biologic exposure and demonstrating a favourable safety profile.
- 10 June 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 64 (6) , 781-791
Real‐World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA Registry
Background and Aims: Risankizumab, a selective interleukin‐23 p19 inhibitor, has demonstrated efficacy in clinical trials for moderate‐to‐severe Crohn's disease, but real‐world data in highly refractory populations are limited. We evaluated the short‐term effectiveness and outcomes at last follow‐up of risankizumab and the impact of prior advanced therapy exposure. Methods: This multicentre observational study included adult patients with predominantly refractory Crohn's disease treated with risankizumab and registered in the ENEIDA registry. Steroid‐free clinical remission, defined as a Harvey–Bradshaw Index ≤ 4 without systemic corticosteroids, was assessed at weeks 8–12 and at the last available follow‐up visit. Multivariable logistic regression was used to identify factors associated with remission at last follow‐up. Results: A total of 857 patients with predominantly refractory Crohn's disease were included. Steroid‐free clinical remission was achieved in 56% of patients at weeks 8–12 and in 61% at last follow‐up (mean follow‐up: 7.4 months). Remission rates were higher in patients previously exposed to ≤ 2 biologic therapies than in those exposed to > 2 biologic therapies at both time points ( p < 0.001). Prior ustekinumab exposure was associated with lower remission rates in unadjusted analyses but was not independently associated with remission at last follow‐up. Treatment‐related adverse events occurred in 8% of patients, with no serious adverse events. Conclusions: In this large real‐world cohort of patients with refractory Crohn's disease, risankizumab achieved clinically meaningful steroid‐free clinical remission, both at early assessment and at last follow‐up, with effectiveness primarily influenced by cumulative biologic exposure and demonstrating a favourable safety profile.
- Open Access
- 5 June 2026
- Published by Springer Nature in BMC Gastroenterology
- Vol. 26 (1)
Training satisfaction, competency gaps and well-being in gastroenterology residency in Spain: results of a national SEPD survey
To explore the training experience, competency needs and professional wellbeing of Gastroenterology trainees in Spain, with a particular focus on factors associated with burnout. We conducted a cross-sectional study using an anonymous online survey distributed to residents (R1-R4) and young specialists (≤ 5 years after completing the training program). The survey collected information on training satisfaction, perceived competency gaps, working conditions, and burnout. Responses were collected using 5-point Likert scales. Descriptive analyses, subgroup comparisons and logistic regression models were used to identify factors associated with burnout. A total of 241 responses were obtained (60.6% women; mean age 30.2 ± 3.6 years). Nearly all participants trained in university hospitals (97.5%) and most in tertiary centres (82.6%). Overall satisfaction with the training program was 3.99 ± 0.71/5, with practical training rated more favourably (4.25 ± 0.71) than theoretical training (3.30 ± 0.98). The main areas identified as needing reinforcement were clinical nutrition (26.0%), digestive ultrasonography (25.2%) and endoscopy (23.3%). Burnout was reported by 63.5% of respondents. Lack of adequate rest was strongly associated with higher burnout risk, while satisfaction with working conditions showed a protective effect, an association that remained significant in multivariate analysis. Additionally, 89.5% believed that an additional year would improve their preparation, and 97.1% considered that a five-year program would be sufficient to acquire the necessary competencies. While practical training is highly valued, gaps persist in theoretical education and key technical areas. Burnout is common and closely linked to insufficient rest and dissatisfaction with working conditions. The strong support for extending residency to five years suggests that this measure may not only enhance training quality but also promote wellbeing and a more balanced acquisition of competencies.
- 5 June 2026
- Published by Springer Nature in BMC Gastroenterology
- Vol. 26 (1)
Open AccessTraining satisfaction, competency gaps and well-being in gastroenterology residency in Spain: results of a national SEPD survey
To explore the training experience, competency needs and professional wellbeing of Gastroenterology trainees in Spain, with a particular focus on factors associated with burnout. We conducted a cross-sectional study using an anonymous online survey distributed to residents (R1-R4) and young specialists (≤ 5 years after completing the training program). The survey collected information on training satisfaction, perceived competency gaps, working conditions, and burnout. Responses were collected using 5-point Likert scales. Descriptive analyses, subgroup comparisons and logistic regression models were used to identify factors associated with burnout. A total of 241 responses were obtained (60.6% women; mean age 30.2 ± 3.6 years). Nearly all participants trained in university hospitals (97.5%) and most in tertiary centres (82.6%). Overall satisfaction with the training program was 3.99 ± 0.71/5, with practical training rated more favourably (4.25 ± 0.71) than theoretical training (3.30 ± 0.98). The main areas identified as needing reinforcement were clinical nutrition (26.0%), digestive ultrasonography (25.2%) and endoscopy (23.3%). Burnout was reported by 63.5% of respondents. Lack of adequate rest was strongly associated with higher burnout risk, while satisfaction with working conditions showed a protective effect, an association that remained significant in multivariate analysis. Additionally, 89.5% believed that an additional year would improve their preparation, and 97.1% considered that a five-year program would be sufficient to acquire the necessary competencies. While practical training is highly valued, gaps persist in theoretical education and key technical areas. Burnout is common and closely linked to insufficient rest and dissatisfaction with working conditions. The strong support for extending residency to five years suggests that this measure may not only enhance training quality but also promote wellbeing and a more balanced acquisition of competencies.
- Open Access
- 9 May 2026
- Published by Wiley in United European Gastroenterology Journal
- Vol. 14 (4) , e70214
Effect of Mirikizumab on Clinical and Endoscopic Outcomes Based on Prior Advanced Therapy Failure in Patients With Moderately to Severely Active Ulcerative Colitis
Background: Mirikizumab demonstrated efficacy in moderately‐to‐severely active ulcerative colitis, including in patients with prior advanced therapy failure (PATF) (Phase 3: LUCENT‐1 [NCT03518086], LUCENT‐2 [NCT03524092]). This post hoc analysis evaluates mirikizumab efficacy by number/mechanism of PATF. Methods: LUCENT‐1 patients received 300 mg mirikizumab or placebo; mirikizumab induction responders entered LUCENT‐2 and received 200 mg mirikizumab or placebo until week (W)52. Mirikizumab induction non‐responders received extended induction with open‐label 300 mg mirikizumab between W12 and W24. Extended induction responders received open‐label 200 mg mirikizumab between W24 and W52. In each population, efficacy was analyzed by subgroups based on PATF number (0, 1, ≥ 2 [2–3]) and mechanism (including difficult‐to‐treat [DTT]: anti‐TNF plus tofacitinib and/or vedolizumab). Results: At baseline, 479/1162 patients (41.2%) had (≥ 1) PATF, of which 177 (37.0%) had DTT. Among mirikizumab‐treated patients ( n = 868), W12 clinical response was achieved by 69.8%, 63.9%, 45.3%, and 41.9% of the 0‐PATF, 1‐PATF, ≥ 2‐PATF, and DTT subgroups, respectively. 42.1% (365/868) continued with maintenance treatment. Among W12 responders, 51.9% (0‐PATF), 44.2% (1‐PATF), 49.0% (≥ 2‐PATF), and 42.9% (DTT) achieved clinical remission at W52. Over half of the patients (54.0% [147/272]) in the extended induction population had PATF; 51.0% (75/147) were DTT. At W24, clinical response was achieved by 62.4%, 41.4%, 49.5%, and 49.3% of the 0‐PATF, 1‐PATF, ≥ 2‐PATF, and DTT subgroups. Of this 49.3% of the DTT subgroup (extended induction responders), 38.9% (14/36) achieved W52 clinical remission. Conclusions: Mirikizumab induction and maintenance is efficacious in moderately‐to‐severely active ulcerative colitis with or without prior failure of advanced therapy, including difficult‐to‐treat disease. Trail Registration: LUCENT‐1: NCT03518086; LUCENT‐2: NCT03524092
- 9 May 2026
- Published by Wiley in United European Gastroenterology Journal
- Vol. 14 (4) , e70214
Open AccessEffect of Mirikizumab on Clinical and Endoscopic Outcomes Based on Prior Advanced Therapy Failure in Patients With Moderately to Severely Active Ulcerative Colitis
Background: Mirikizumab demonstrated efficacy in moderately‐to‐severely active ulcerative colitis, including in patients with prior advanced therapy failure (PATF) (Phase 3: LUCENT‐1 [NCT03518086], LUCENT‐2 [NCT03524092]). This post hoc analysis evaluates mirikizumab efficacy by number/mechanism of PATF. Methods: LUCENT‐1 patients received 300 mg mirikizumab or placebo; mirikizumab induction responders entered LUCENT‐2 and received 200 mg mirikizumab or placebo until week (W)52. Mirikizumab induction non‐responders received extended induction with open‐label 300 mg mirikizumab between W12 and W24. Extended induction responders received open‐label 200 mg mirikizumab between W24 and W52. In each population, efficacy was analyzed by subgroups based on PATF number (0, 1, ≥ 2 [2–3]) and mechanism (including difficult‐to‐treat [DTT]: anti‐TNF plus tofacitinib and/or vedolizumab). Results: At baseline, 479/1162 patients (41.2%) had (≥ 1) PATF, of which 177 (37.0%) had DTT. Among mirikizumab‐treated patients ( n = 868), W12 clinical response was achieved by 69.8%, 63.9%, 45.3%, and 41.9% of the 0‐PATF, 1‐PATF, ≥ 2‐PATF, and DTT subgroups, respectively. 42.1% (365/868) continued with maintenance treatment. Among W12 responders, 51.9% (0‐PATF), 44.2% (1‐PATF), 49.0% (≥ 2‐PATF), and 42.9% (DTT) achieved clinical remission at W52. Over half of the patients (54.0% [147/272]) in the extended induction population had PATF; 51.0% (75/147) were DTT. At W24, clinical response was achieved by 62.4%, 41.4%, 49.5%, and 49.3% of the 0‐PATF, 1‐PATF, ≥ 2‐PATF, and DTT subgroups. Of this 49.3% of the DTT subgroup (extended induction responders), 38.9% (14/36) achieved W52 clinical remission. Conclusions: Mirikizumab induction and maintenance is efficacious in moderately‐to‐severely active ulcerative colitis with or without prior failure of advanced therapy, including difficult‐to‐treat disease. Trail Registration: LUCENT‐1: NCT03518086; LUCENT‐2: NCT03524092
- Open Access
- 30 April 2026
- Published by Wiley in United European Gastroenterology Journal
- Vol. 14 (4) , e70223
Real‐World Effectiveness and Safety of Upadacitinib in Crohn's Disease: Insights From the Eneida Registry
Background: Upadacitinib (UPA) is the first oral Janus kinase (JAK) inhibitor approved for the treatment of Crohn's disease (CD). Real‐world data, particularly from large nationwide cohorts, remain limited. This study aimed to evaluate the real‐world effectiveness, safety, and treatment persistence of UPA in patients with CD. Methods: Multicenter observational study including patients with CD who received UPA, using data from a nationwide registry. Patients were classified according to active luminal disease, extraintestinal manifestations (EIMs), or combination therapy with another biological therapy. Disease activity was assessed using the Harvey–Bradshaw Index (HBI), C‐reactive protein (CRP), and fecal calprotectin (FC) at baseline and weeks 12, 24, and 52. Endoscopic outcomes were evaluated when available. Adverse events (AEs), hospitalizations, and treatment discontinuations were recorded. Results: 300 patients were included, representing a highly treatment‐refractory population, with 98% previously exposed to anti‐TNF agents and 59% to three or more advanced therapies. In those treated for active luminal disease, corticosteroid‐free clinical remission was achieved in 60%–62% of patients at weeks 12, 24 and 52. CRP normalization increased from 64% at week 12%–74% at week 52, while FC normalization improved from 48% to 64%. Patients treated for EIMs achieved high and sustained remission rates with excellent treatment persistence. Early remission at week 12 was strongly associated with sustained remission and meaningful endoscopic improvement. UPA was discontinued in 98 patients (39%). AEs were reported in 71 patients (24%). Conclusions: In this large real‐world cohort, UPA demonstrated sustained clinical and biochemical effectiveness, meaningful endoscopic response, and a safety profile consistent with clinical trial data. Early response emerged as a key predictor of long‐term outcomes, supporting the clinical utility of UPA.
- 30 April 2026
- Published by Wiley in United European Gastroenterology Journal
- Vol. 14 (4) , e70223
Open AccessReal‐World Effectiveness and Safety of Upadacitinib in Crohn's Disease: Insights From the Eneida Registry
Background: Upadacitinib (UPA) is the first oral Janus kinase (JAK) inhibitor approved for the treatment of Crohn's disease (CD). Real‐world data, particularly from large nationwide cohorts, remain limited. This study aimed to evaluate the real‐world effectiveness, safety, and treatment persistence of UPA in patients with CD. Methods: Multicenter observational study including patients with CD who received UPA, using data from a nationwide registry. Patients were classified according to active luminal disease, extraintestinal manifestations (EIMs), or combination therapy with another biological therapy. Disease activity was assessed using the Harvey–Bradshaw Index (HBI), C‐reactive protein (CRP), and fecal calprotectin (FC) at baseline and weeks 12, 24, and 52. Endoscopic outcomes were evaluated when available. Adverse events (AEs), hospitalizations, and treatment discontinuations were recorded. Results: 300 patients were included, representing a highly treatment‐refractory population, with 98% previously exposed to anti‐TNF agents and 59% to three or more advanced therapies. In those treated for active luminal disease, corticosteroid‐free clinical remission was achieved in 60%–62% of patients at weeks 12, 24 and 52. CRP normalization increased from 64% at week 12%–74% at week 52, while FC normalization improved from 48% to 64%. Patients treated for EIMs achieved high and sustained remission rates with excellent treatment persistence. Early remission at week 12 was strongly associated with sustained remission and meaningful endoscopic improvement. UPA was discontinued in 98 patients (39%). AEs were reported in 71 patients (24%). Conclusions: In this large real‐world cohort, UPA demonstrated sustained clinical and biochemical effectiveness, meaningful endoscopic response, and a safety profile consistent with clinical trial data. Early response emerged as a key predictor of long‐term outcomes, supporting the clinical utility of UPA.
- Open Access
Usefulness of Nutritional Intervention Through New Digital Technologies in Patients with Inflammatory Bowel Disease
Background: Malnutrition and suboptimal diet quality are common, yet under-recognized, in inflammatory bowel disease (IBD) and are associated with worse clinical outcomes and lower quality of life. Digital tools may facilitate continuous, personalized nutritional support, but evidence in IBD remains limited. The aim of this study was to evaluate the impact of a nutritional intervention based on a mobile application (Nootric®) on nutritional status, diet quality, and malnutrition risk in patients with IBD undergoing stable follow-up. Methods: We conducted a prospective longitudinal cohort study without a control group including 151 adult patients with Crohn’s disease or ulcerative colitis under stable follow-up in a tertiary IBD unit. Participants used a structured digital nutritional support program through the Nootric® app for 24 weeks, supervised by dietitians and the IBD team. Clinical activity, biochemical markers (C-reactive protein, fecal calprotectin), nutritional biomarkers (albumin, prealbumin, micronutrients), body mass index (BMI), malnutrition risk (self-administered Malnutrition Universal Screening Tool, MUST), and diet quality (PREDIMED and an expanded “Nootric score”) were assessed at baseline, 12 weeks, and 24 weeks. Analyses focused on patients with adequate adherence. Results: Of the 151 included IBD patients, 110 maintained stable app use. Mean albumin increased from 4.38 to 4.49 g/dL at 24 weeks (p = 0.003), and prealbumin from 24.9 to 26.1 mg/dL (p = 0.047), despite the absence of overt protein–calorie malnutrition at baseline. Patients with obesity achieved a mean weight loss of approximately 6% of baseline body weight. Diet quality improved significantly, with higher Nootric score and a positive correlation between app use intensity and increased score. Malnutrition risk according to the MUST scale improved in more adherent patients, while clinical and biochemical disease activity remained stable overall. Conclusions: A mobile app-based nutritional program supervised by dietitians was feasible, well accepted, and associated with improved nutritional markers, diet quality, and malnutrition risk, supporting its role as a complementary component of IBD care.
Open AccessUsefulness of Nutritional Intervention Through New Digital Technologies in Patients with Inflammatory Bowel Disease
Background: Malnutrition and suboptimal diet quality are common, yet under-recognized, in inflammatory bowel disease (IBD) and are associated with worse clinical outcomes and lower quality of life. Digital tools may facilitate continuous, personalized nutritional support, but evidence in IBD remains limited. The aim of this study was to evaluate the impact of a nutritional intervention based on a mobile application (Nootric®) on nutritional status, diet quality, and malnutrition risk in patients with IBD undergoing stable follow-up. Methods: We conducted a prospective longitudinal cohort study without a control group including 151 adult patients with Crohn’s disease or ulcerative colitis under stable follow-up in a tertiary IBD unit. Participants used a structured digital nutritional support program through the Nootric® app for 24 weeks, supervised by dietitians and the IBD team. Clinical activity, biochemical markers (C-reactive protein, fecal calprotectin), nutritional biomarkers (albumin, prealbumin, micronutrients), body mass index (BMI), malnutrition risk (self-administered Malnutrition Universal Screening Tool, MUST), and diet quality (PREDIMED and an expanded “Nootric score”) were assessed at baseline, 12 weeks, and 24 weeks. Analyses focused on patients with adequate adherence. Results: Of the 151 included IBD patients, 110 maintained stable app use. Mean albumin increased from 4.38 to 4.49 g/dL at 24 weeks (p = 0.003), and prealbumin from 24.9 to 26.1 mg/dL (p = 0.047), despite the absence of overt protein–calorie malnutrition at baseline. Patients with obesity achieved a mean weight loss of approximately 6% of baseline body weight. Diet quality improved significantly, with higher Nootric score and a positive correlation between app use intensity and increased score. Malnutrition risk according to the MUST scale improved in more adherent patients, while clinical and biochemical disease activity remained stable overall. Conclusions: A mobile app-based nutritional program supervised by dietitians was feasible, well accepted, and associated with improved nutritional markers, diet quality, and malnutrition risk, supporting its role as a complementary component of IBD care.
- 12 March 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 63 (12) , 1605-1616
Post‐Operative Recurrence of Colonic Crohn's Disease After Colectomy: The RESECOL Study by the Young Group of GETECCU
Background and Aims: Post‐operative recurrence (POR) of colonic Crohn's Disease (CD) after segmental (SC) or subtotal colectomy (STC) is scarcely described. Therefore, we aimed to report the rates and predictors of POR in this setting. Methods: Multicentre, nationwide, retrospective study including colonic CD patients undergoing SC or STC. Clinical, endoscopic, radiologic and surgical POR were assessed and POR‐free survival was compared between procedures. Cox regression determined predictors of post‐colectomy POR. Inverse probability of treatment weighting (IPTW) was carried out for sensitivity analyses. Results: A total of 224 patients were included (157 SC, 67 STC). Clinical POR occurred less frequently after SC than after STC (38% vs 63%, p = 0.001), as did endoscopic POR (50% vs 71%, p = 0.012); whereas radiologic and surgical POR rates were similar ( p = 0.1 and p = 0.992, respectively). Clinical POR‐free survival at 1 and 5 years was higher after SC than after STC (82% and 64.8% vs 67.6% and 39%, log‐rank p = 0.001). Endoscopic POR‐free survival followed a similar pattern (log‐rank p < 0.001). In multivariable Cox regression, SC remained protective against clinical (HR 0.54 [0.36–0.81]) and early endoscopic POR (HR 0.54 [0.35–0.82]). After IPTW, SC was still associated with a significantly lower risk of clinical and endoscopic POR. Conclusion: Clinical and endoscopic POR rates are significantly lower following SC compared with STC in colonic CD, while radiologic and surgical recurrence rates were similar. SC shows a protective effect regarding clinical and early endoscopic POR. These data support segmental resection of colonic CD when feasible.
- 12 March 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 63 (12) , 1605-1616
Post‐Operative Recurrence of Colonic Crohn's Disease After Colectomy: The RESECOL Study by the Young Group of GETECCU
Background and Aims: Post‐operative recurrence (POR) of colonic Crohn's Disease (CD) after segmental (SC) or subtotal colectomy (STC) is scarcely described. Therefore, we aimed to report the rates and predictors of POR in this setting. Methods: Multicentre, nationwide, retrospective study including colonic CD patients undergoing SC or STC. Clinical, endoscopic, radiologic and surgical POR were assessed and POR‐free survival was compared between procedures. Cox regression determined predictors of post‐colectomy POR. Inverse probability of treatment weighting (IPTW) was carried out for sensitivity analyses. Results: A total of 224 patients were included (157 SC, 67 STC). Clinical POR occurred less frequently after SC than after STC (38% vs 63%, p = 0.001), as did endoscopic POR (50% vs 71%, p = 0.012); whereas radiologic and surgical POR rates were similar ( p = 0.1 and p = 0.992, respectively). Clinical POR‐free survival at 1 and 5 years was higher after SC than after STC (82% and 64.8% vs 67.6% and 39%, log‐rank p = 0.001). Endoscopic POR‐free survival followed a similar pattern (log‐rank p < 0.001). In multivariable Cox regression, SC remained protective against clinical (HR 0.54 [0.36–0.81]) and early endoscopic POR (HR 0.54 [0.35–0.82]). After IPTW, SC was still associated with a significantly lower risk of clinical and endoscopic POR. Conclusion: Clinical and endoscopic POR rates are significantly lower following SC compared with STC in colonic CD, while radiologic and surgical recurrence rates were similar. SC shows a protective effect regarding clinical and early endoscopic POR. These data support segmental resection of colonic CD when feasible.
- Open Access
- 5 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (5) , 2001
Factors Influencing Clinical and Radiological Response in Perianal Disease: Results from a Real-World Cohort Treated with Anti-TNF Therapy
Background: Perianal Crohn’s disease (PD) remains a major therapeutic challenge, with heterogeneous responses to anti-TNF therapy and limited real-world data on predictors of long-term outcomes. This study aimed to evaluate clinical and radiological response to anti-TNF therapy initiated exclusively for PD and to identify factors associated with treatment response. Methods: A retrospective study was conducted in a cohort of 65 patients with PD treated with anti-TNF. The primary endpoint was clinical response assessed at weeks 24, 52, and 60 months. It was defined as a ≥50% reduction in drainage, and remission as complete absence of drainage. Radiological response was assessed by magnetic resonance imaging at the same time points whenever feasible. Multivariate logistic regression analyses were performed to identify independent predictors of response. Results: At week 24, 84.6% of patients achieved a clinical response, while radiological response was observed in 30.8%. At week 52, clinical and radiological response rates were 80.0% and 52.3%, respectively. At 60 months, 61.5% maintained clinical response and 46.1% radiological response. Among patients who responded at week 24, 90.7% maintained response at week 52, with a secondary loss of response rate of 9.3%. Multivariate analysis identified absence of antineutrophil cytoplasmic antibodies (ANCA) as an independent predictor of clinical response at week 52 (OR 0.06, 95% CI 0.006–0.59; p = 0.01). No significant associations were observed between anti-TNF serum levels and clinical or radiological outcomes. Conclusions: In this real-world cohort of patients initiating anti-TNF exclusively for PD, early response (week 24) emerged as a potential marker of long-term outcomes, highlighting the importance of early reassessment and individualized therapeutic strategies.
- 5 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (5) , 2001
Open AccessFactors Influencing Clinical and Radiological Response in Perianal Disease: Results from a Real-World Cohort Treated with Anti-TNF Therapy
Background: Perianal Crohn’s disease (PD) remains a major therapeutic challenge, with heterogeneous responses to anti-TNF therapy and limited real-world data on predictors of long-term outcomes. This study aimed to evaluate clinical and radiological response to anti-TNF therapy initiated exclusively for PD and to identify factors associated with treatment response. Methods: A retrospective study was conducted in a cohort of 65 patients with PD treated with anti-TNF. The primary endpoint was clinical response assessed at weeks 24, 52, and 60 months. It was defined as a ≥50% reduction in drainage, and remission as complete absence of drainage. Radiological response was assessed by magnetic resonance imaging at the same time points whenever feasible. Multivariate logistic regression analyses were performed to identify independent predictors of response. Results: At week 24, 84.6% of patients achieved a clinical response, while radiological response was observed in 30.8%. At week 52, clinical and radiological response rates were 80.0% and 52.3%, respectively. At 60 months, 61.5% maintained clinical response and 46.1% radiological response. Among patients who responded at week 24, 90.7% maintained response at week 52, with a secondary loss of response rate of 9.3%. Multivariate analysis identified absence of antineutrophil cytoplasmic antibodies (ANCA) as an independent predictor of clinical response at week 52 (OR 0.06, 95% CI 0.006–0.59; p = 0.01). No significant associations were observed between anti-TNF serum levels and clinical or radiological outcomes. Conclusions: In this real-world cohort of patients initiating anti-TNF exclusively for PD, early response (week 24) emerged as a potential marker of long-term outcomes, highlighting the importance of early reassessment and individualized therapeutic strategies.
- Open Access
- 4 March 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1753914
T cell and cytokine signatures as early predictors of response to IL-12/IL-23 inhibition in Crohn’s disease
Introduction: Crohn’s disease (CD) is a disabling inflammatory disorder with highly variable response to biologic therapies. Despite the availability of multiple biologic agents, a significant proportion of patients experience primary non-response, while others initially respond but subsequently develop secondary loss of response, leading to sequential treatment failures and increased healthcare burden. The disease course and response to treatment are remarkably heterogeneous among patients, and a better understanding of the personalised pathways affected is required. Identifying early biomarkers of treatment efficacy is crucial for improving patient outcomes and reducing unnecessary healthcare costs. Methods: In this study, we comprehensively analysed T cell subpopulations in blood and lamina propria, together with serum cytokine profiles, in CD patients receiving the IL-12/IL-23 inhibitor ustekinumab. Results: The most remarkable findings were observed in peripheral blood. At week 24, good responders showed decreased Th1, increased Th2, and reduced IL-17A serum levels compared with non-responders. Importantly, elevated IL-12/IL-23 serum levels at week 8 associated with favourable clinical and endoscopic outcomes, suggesting effective pathway blockade. Discussion: These findings support the measurement of serum IL-12/IL-23 at week 8 as a simple, early predictor of ustekinumab response in CD, potentially guiding personalised treatment strategies and ultimately long-term response.
- 4 March 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1753914
Open AccessT cell and cytokine signatures as early predictors of response to IL-12/IL-23 inhibition in Crohn’s disease
Introduction: Crohn’s disease (CD) is a disabling inflammatory disorder with highly variable response to biologic therapies. Despite the availability of multiple biologic agents, a significant proportion of patients experience primary non-response, while others initially respond but subsequently develop secondary loss of response, leading to sequential treatment failures and increased healthcare burden. The disease course and response to treatment are remarkably heterogeneous among patients, and a better understanding of the personalised pathways affected is required. Identifying early biomarkers of treatment efficacy is crucial for improving patient outcomes and reducing unnecessary healthcare costs. Methods: In this study, we comprehensively analysed T cell subpopulations in blood and lamina propria, together with serum cytokine profiles, in CD patients receiving the IL-12/IL-23 inhibitor ustekinumab. Results: The most remarkable findings were observed in peripheral blood. At week 24, good responders showed decreased Th1, increased Th2, and reduced IL-17A serum levels compared with non-responders. Importantly, elevated IL-12/IL-23 serum levels at week 8 associated with favourable clinical and endoscopic outcomes, suggesting effective pathway blockade. Discussion: These findings support the measurement of serum IL-12/IL-23 at week 8 as a simple, early predictor of ustekinumab response in CD, potentially guiding personalised treatment strategies and ultimately long-term response.
- Open Access
- 1 March 2026
- Published by Korean Society of Ultrasound in Medicine in Ultrasonography
- Vol. 45 (2) , 107-118
Monitoring of low-risk pancreatic cystic lesions with targeted abdominal ultrasound: diagnostic yield, clinical utility, and acceptance
Purpose: This study aimed to evaluate the utility of targeted abdominal ultrasound (TAUS) for follow-up of low-risk pancreatic cystic lesions (PCLs), assessing diagnostic performance, agreement with advanced imaging, patient acceptance, clinical usefulness, and contribution of structured reporting.Methods: This prospective study included 120 patients with low-risk PCLs previously characterized by magnetic resonance cholangiopancreatography or endoscopic ultrasound. TAUS was performed using a wideband convex matrix probe (1.8–6.2 MHz) and a structured protocol documenting lesion location, size, morphology (septa, mural nodules), and relation to the main pancreatic duct. Contrast-enhanced ultrasound (CEUS) was used in selected cases. Outcomes included agreement with reference imaging (intraclass correlation coefficient [ICC]), patient preference, and perceived usefulness.Results: TAUS enabled complete pancreatic visualization in 80.0% of patients and overall detection rate in 88.3%. Detection varied by location (P=0.028), highest in the body (94.5%) and lowest in the tail (68.0%). Agreement for maximal cyst diameter was excellent (ICC, 0.98; 95% confidence interval, 0.971 to 0.986), with 90.8% of measurements within ±20% of the reference modality. When B-mode was suboptimal, CEUS was used in 2.5% of cases and improved delineation of architecture (mural nodules, septations). Limitations included low detection of multifocal disease (11.1%) and restricted assessment of ductal communication (46.6%). TAUS was clinically useful in 78.0% and preferred by patients when characterization was adequate (88.3%).Conclusion: TAUS is a promising noninvasive imaging tool for monitoring low-risk PCLs in favorable acoustic windows, showing high diagnostic accuracy, excellent agreement with advanced imaging, and strong patient acceptance. Its diagnostic performance is limited in multifocal, complex, or tail-located lesions.
- 1 March 2026
- Published by Korean Society of Ultrasound in Medicine in Ultrasonography
- Vol. 45 (2) , 107-118
Open AccessMonitoring of low-risk pancreatic cystic lesions with targeted abdominal ultrasound: diagnostic yield, clinical utility, and acceptance
Purpose: This study aimed to evaluate the utility of targeted abdominal ultrasound (TAUS) for follow-up of low-risk pancreatic cystic lesions (PCLs), assessing diagnostic performance, agreement with advanced imaging, patient acceptance, clinical usefulness, and contribution of structured reporting.Methods: This prospective study included 120 patients with low-risk PCLs previously characterized by magnetic resonance cholangiopancreatography or endoscopic ultrasound. TAUS was performed using a wideband convex matrix probe (1.8–6.2 MHz) and a structured protocol documenting lesion location, size, morphology (septa, mural nodules), and relation to the main pancreatic duct. Contrast-enhanced ultrasound (CEUS) was used in selected cases. Outcomes included agreement with reference imaging (intraclass correlation coefficient [ICC]), patient preference, and perceived usefulness.Results: TAUS enabled complete pancreatic visualization in 80.0% of patients and overall detection rate in 88.3%. Detection varied by location (P=0.028), highest in the body (94.5%) and lowest in the tail (68.0%). Agreement for maximal cyst diameter was excellent (ICC, 0.98; 95% confidence interval, 0.971 to 0.986), with 90.8% of measurements within ±20% of the reference modality. When B-mode was suboptimal, CEUS was used in 2.5% of cases and improved delineation of architecture (mural nodules, septations). Limitations included low detection of multifocal disease (11.1%) and restricted assessment of ductal communication (46.6%). TAUS was clinically useful in 78.0% and preferred by patients when characterization was adequate (88.3%).Conclusion: TAUS is a promising noninvasive imaging tool for monitoring low-risk PCLs in favorable acoustic windows, showing high diagnostic accuracy, excellent agreement with advanced imaging, and strong patient acceptance. Its diagnostic performance is limited in multifocal, complex, or tail-located lesions.